Regeneron Pharmaceuticals Inc

Financials

Cash from operating activities 2.62 B7.08 B5.01 B4.59 B4.42 B4.98 B 4.98 B Cash from investing activities 70.6 M5.38 B3.78 B3.19 B2.47 B629.1 M 629.1 M Cash from financing activities 1.97 B1.01 B1.01 B1.79 B2.2 B3.72 B 3.72 B Free cash flow 2 B6.53 B4.42 B3.88 B3.66 B4.08 B 4.08 B

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

REGN

Financials

Regeneron Pharmaceuticals Inc

新闻

10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)

Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline

Ionis Pharmaceuticals Stock: Digesting Recent Events (NASDAQ:IONS)

国泰海通：FXI引领抗凝药产业新变革多技术路线竞逐蓝海

Electromed Stock: How Far Can This Microcap Go Before Their Market Collapses? (NYSE:ELMD)

Why IBD Stock Of The Day Harrow Has Its Sights On A Breakout

Should You Buy ANI Pharmaceuticals Stock Before Q4 Earnings?

再生元治疗FOP药物获FDA优先审评资格

FDA grants priority review for Regeneron’s FOP treatment

Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes - Ocular Therapeutix (NASDAQ:OCUL)

The Week That Was, The Week Ahead: Macro and Markets, Feb. 15 - TipRanks.com

Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y